Alpha 2.0
Login Register
» Authors » Kaitlyn J Andreano

Kaitlyn J Andreano

Explore the profile of Kaitlyn J Andreano including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 99
Followers 0
Related Specialties
Oncology
General Medicine
Top 10 Co-Authors
Donald P McDonnell
John D Norris
Suzanne E Wardell
Kendall A Heetderks
Christina A Chao
Taylor K Desautels
Yeeun Bae
Jennifer G Baker
Jeremy T Blitzer
SungHee Park
Published In
Breast Cancer Res Treat
J Clin Invest
Mol Cancer Ther
Gynecol Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
The Dysregulated Pharmacology of Clinically Relevant Mutants is Normalized by Ligand-activated WT Receptor
Andreano K, Baker J, Park S, Safi R, Artham S, Oesterreich S, et al.
Mol Cancer Ther . 2020 May; 19(7):1395-1405. PMID: 32381587
The estrogen receptor (ER/) is expressed in a majority of breast cancers and drugs that inhibit ER signaling are the cornerstone of breast cancer pharmacotherapy. Currently, aromatase inhibitors are the...
2.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
Andreano K, Wardell S, Baker J, Desautels T, Baldi R, Chao C, et al.
Breast Cancer Res Treat . 2020 Mar; 180(3):635-646. PMID: 32130619
Purpose: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However,...
3.
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Wardell S, Yllanes A, Chao C, Bae Y, Andreano K, Desautels T, et al.
Breast Cancer Res Treat . 2019 Nov; 179(3):769. PMID: 31734822
The article Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy, written by Suzanne...
4.
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Wardell S, Yllanes A, Chao C, Bae Y, Andreano K, Desautels T, et al.
Breast Cancer Res Treat . 2019 Sep; 179(1):67-77. PMID: 31562570
Purpose: Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol...
5.
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies
Gaillard S, Andreano K, Gay L, Steiner M, Jorgensen M, Davidson B, et al.
Gynecol Oncol . 2019 Apr; 154(1):199-206. PMID: 30987772
Objective: Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy,...
6.
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
Norris J, Ellison S, Baker J, Stagg D, Wardell S, Park S, et al.
J Clin Invest . 2017 May; 127(6):2326-2338. PMID: 28463227
The clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the production of androgens, has been exemplified by the approval of abiraterone for...